Jongdohun Jung, Reporter for the Ministry of Bio, Startups and Venture

Jongdohun Jung, Reporter for the Ministry of Bio, Startups and Venture

View original image

Despite some fluctuations, we are now living in the era of the “Chunsdaq” (KOSDAQ Index at 1,000 points). Amid this celebratory atmosphere, however, “K-Bio” in the KOSDAQ market has been thoroughly left out. The reason was not performance or funding difficulties, but rather an issue of trust.


At the beginning of the year, Alteogen, which had the largest market capitalization on the KOSDAQ, dampened market sentiment. During the JP Morgan Healthcare Conference in mid-January, the company stated, “We expect to close a deal of similar size to the previous one as early as next week.” However, the deal announced was only worth around 420 billion won—far short of the market’s expectations for a trillion-won-scale agreement—causing the stock price to tumble. It was also belatedly revealed that the royalty rate for the subcutaneous (SC) formulation of Keytruda licensed to Merck was only about 2%, not the 5% the market had expected. As a result, the company’s share price is now nearly 30% below its peak in November of last year. Alteogen’s sharp decline, despite being a leading stock for both the KOSDAQ and the biotech sector, led to a cold snap for other bio stocks. ABL Bio also saw its shares fall by 20% on January 30, after news broke that the Parkinson’s disease treatment candidate it licensed to Sanofi had been pushed down in development priority.


Medical artificial intelligence (AI) company Lunit recently carried out a rights offering totaling over 250 billion won, which amounts to more than 20% of its market capitalization. This move was made to ease the burden of the put option on the convertible bonds (CB) issued to acquire New Zealand medical AI company Volpara, by appealing to shareholders for support. While some media outlets recently mentioned the possibility of raising over 200 billion won, the company has consistently dismissed both the size and likelihood of such funding. Over the past three years, the company has conducted rights offerings totaling 450 billion won in an effort to expand its business. This makes their claims that “the company’s fundamentals are strong” ring rather hollow.


Until now, biotech firms have sought survival and expansion by stoking market expectations. As a result, the market’s scale has rapidly grown, with companies surpassing 10 trillion won in market capitalization emerging one after another. However, amid this trend, how much effort has been devoted to calmly and objectively sharing information with shareholders?


Let us recall what drove the Korean stock market to reach new all-time highs. While financial results played a role, the key factors were efforts to improve governance and expectations for restoring market trust, aimed at resolving the “Korea Discount” (undervaluation of the Korean stock market). As the entire market moves toward greater transparency, the methods biotech companies use to communicate with shareholders remain primitive, despite their pride in being part of an advanced industry.



Now, the Korean biotech industry stands on the verge of witnessing the birth of “profit-generating biotechs.” This achievement is the result not only of companies focused on research and development (R&D) and business, but also of shareholders who believed in the potential of biotech and invested. It is time to shed the rosy packaging used for short-term stock price defense. Biotech companies can no longer survive on dreams alone; they must feed on shareholder trust and respond in kind as they grow.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing